RRPV BoNT-NMJ

The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV) and Advanced Technology International (ATI), is issuing a Sources‑Sought Request for Information (RFI) to identify organizations that already operate human‑cell‑based neuromuscular junction (NMJ) micro‑physiological systems (MPS) suitable for botulinum neurotoxin (BoNT) potency testing and medical countermeasure (MCM) evaluation. Respondents must describe their existing NMJ platform (organ‑on‑chip, microfluidic, engineered tissue, MEA‑enabled, etc.), including development stage, throughput, ability to generate dose‑response data (EC50/IC50), differentiation of BoNT serotypes A‑G, cell sources, functional motor‑neuron‑muscle connectivity, reproducibility, sensitivity, and available readouts (muscle contraction, electrophysiology, calcium imaging, SNARE cleavage, neurotransmitter release). Additional required information includes commercial and manufacturing considerations (intellectual property, scalability, material/assembly throughput), operational challenges (access to Select‑Agent‑accredited labs, CRO partnerships, assay throughput for up to eight serial dilutions in duplicate or quadruplicate per run), regulatory qualification pathways (e.g., FDA iSTAND), and any prior U.S. government funding with identified gaps. Responses must be concise (≤ 5 pages, excluding references), clearly mark proprietary content, and be submitted electronically in PDF or Microsoft Word to rrpv@ati.org no later than 1 p.m. ET on 11 May 2026 with the subject line “RFI Response: NMJ MPS Platforms for BoNT Potency Assay.” This RFI is for market research only; it does not constitute a solicitation, and no reimbursement will be provided.

Notice ID

78111dd8f1d54f3783a4e98804f52351

Solicitation Number

SSN-BARDA-04202026

NAICS Code

541714

Classification Code

6505